How this Houston-headquartered company is innovating the future of heart replacement

HOUSTON INNOVATORS PODCAST EPISODE 183

Thomas Vassiliades, CEO of BiVACOR, joins the Houston Innovators Podcast. Photo courtesy of BiVACOR

Heart disease is one of the most common causes of death in the United States — one in five deaths, according to the CDC. But there's not a long-term solutions for patients — even for those lucky enough to have a successful heart transplant. But a Houston-headquartered medical device company is working on one.

BiVACOR has created a technology that, theoretically, could completely replace a patient's heart and last them the rest of their lives.

"The design is critical," says Thomas Vassiliades, CEO of BiVACOR, on the Houston Innovators Podcast. He joined the organization last year after spending 20 years of a heart surgeon, then transitioning to medical device development over a decade ago.

Vassiliades explains the industry's challenges on the show, saying that there's no comprehensive, lasting replacement to the human heart on the market. While some treatments — like transplants and medical devices that partially replace the heart's capabilities — exist, nothing that completely replaces the heart lasts longer than 10 to 12 years.

"The BiVACOR system is based on magnetic levitation," Vassiliades says about the technology. "Our pump is just one moving impeller that sits in the middle of the housing where the blood is. Imagine an artificial heart — the container that has your blood — and the device spinning in the inside — basically a wheel spinning your blood to the rest of your body.

"The device is suspended by magnets — it's not touching anything," he continues. "So, theoretically, the device has no wear and can last as long as the patient can possibly live. That's new to the field."

Daniel Timms, BiVACOR's founder and CTO, knew there had to be a better, more permanent solution and has been working on the technology since he was a postdoctoral student at Queensland University of Technology in Australia. His work took him to Houston's Texas Heart Institute, the "center of the universe when it comes to blood pumps," says Vassiliades.

The company recently raised $18 million in funding to support its growing team and continued growth. BiVACOR is a Class 3 medical device — the most rigorously regulated type of device, so the funding raised will support the company as it continues to meet the FDA's requirements and proceeds into implantation and clinical trials.

While headquartered in Houston and has close ties to THI, most of BiVACOR's team works out of Huntington Beach, California, just 30 minutes away from its manufacturing partner — something that has been critical for the design phase. Other employees work in Europe and Australia, which has resulted in government grant funding. Each market the company works in has a strategic purpose — and Houston's role is testing.

"We're going to be training all our clinical sites in Houston, and we're going to continue to do ongoing testing," he says. "We're very comfortable with the design of the device, ... but there's always more. And we have a long-term plan to iterate on the device to make it even better."

Vassiliades shares more of the challenges he's facing as he commercializes BiVACOR's technology on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


From Your Site Articles
BiVACOR named Thomas Vassiliades as CEO effective immediately. Photo courtesy of BiVACOR

Former Medtronic exec takes the helm of Houston med device startup

mover and shaker

A Houston-based preclinical artificial heart device company has a new head honcho as it grows its team and further develops its technology.

BiVACOR named Thomas Vassiliades as CEO effective immediately. He replaces the company's founder, Daniel Timms, in the position. BiVACOR is on track to head toward human clinical trials and commercialization, and Vassiliades is tasked with leading the way.

“BiVACOR led an extensive CEO search, and Tom was the clear choice given his experience, background, leadership style, and exceptional track record,” says Timms in a news release. “Tom has the skillset and credibility to guide BiVACOR through its next chapter of transformation and advancement as we undertake the next stage of clinical activities leading up to First in Human early feasibility studies.”

Vassiliades has over 30 years of experience within the medical device industry as well as cardiothoracic surgery. He was most recently the general manager of the surgery and heart failure business at Abiomed and held several leadership roles at Medtronic. Dr. Vassiliades received his MD from the University of North Carolina, and his MBA was achieved with distinction at Emory University.

“I am excited and honored to join the BiVACOR team, working closely with Daniel and the entire team as we look forward to bringing this life-changing technology to the market,” says Dr. Vassiliades in the release. “Throughout my career, I’ve been guided by the goal of bringing innovative cardiovascular therapies to the market to improve patient care and outcomes – providing solutions for those that don’t have one. BiVACOR is uniquely well-positioned to provide long-term therapy for patients with severe biventricular heart failure.”

Timms will take over BiVACOR's technical team working on the Total Artificial Heart system as CTO. The device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

The medical device company, which has operations in Houston and Australia, recently announced the addition of eight new employees doubling their team. The growth comes following its series B raise last year.

“It is a testament to the great progress the team has made and to the importance of the unmet clinical need addressed by the Total artificial Heart technology," Timms says on the appointment of Vassiliades. "We look forward to Tom’s leadership as BiVACOR navigates the path to commercialization.”

In the latest round up of Houston innovation news you may have missed, a health tech startup has grown its team, a coworking company opens its latest location, and more. Shobeir Ansar/Getty Images

Houston named a top market for remote tech workers, startup doubles its staff, and more innovation news

short stories

Houston is starting 2022 strong in terms of innovation news, and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, the Bayou City is ranked based on its ability to employ remote tech talent, a coworking company opens a new location, a med device startup doubles its staff, and more.

New report finds Houston a top market for remote tech talent

Houston is a top city for employing remote tech workers. Graphic via Karat

In a new report, Karat — a Seattle-based human resources company — looked at which metros were best for attracting remote tech talent. The company first completed the report based on 2020 due to a changing workforce spurred by the pandemic.

"Last year we took our first look at the rapidly expanding remote software engineer hiring landscape. As more organizations shifted to remote or hybrid working models we had started to see significantly improving candidate performance outside of the more-established tech hubs," writes Patrick Wu, data analyst at Karat, in a blog post. "Today, as even more top tech companies commit to hiring remote software engineers, we’re taking a look at how this landscape has continued to evolve."

Houston ranked No. 6 this year in the list of 10 metros just ahead of No. 7 Austin. Last year, Houston ranked as No. 2 and Dallas at No. 9, but that North Texas metro fell off the top 10 for 2021. Pittsburgh maintained its top spot on this list year over year.

Houston artificial heart company makes strategic hires

This med device company has eight new team members. Photo via bivacor.com

BiVACOR, a Houston-based cardiatric medical device company, announced that it has doubled the size of its team with the addition of eight team members. The growth comes following its series B raise last year.

“The diversity of skills and experience throughout the company is something we are very proud of, and I am pleased to welcome this all-star group of individuals to the team,” says Daniel Timms, BiVACOR founder and CEO, in a December news release. “They will each play an integral role in the overall accomplishments of BiVACOR, specifically as we undertake benchtop and preclinical verification activities so that we can commence our First in Human early feasibility study in the near future.”

Here's who recently joined the company at both its United States and Australia-based operations:

  • Nathan Kong, purchasing administrator
  • Farhad Akhavan, systems engineer
  • David Duarte, verification and validation engineer
  • Paul Chiver, manufacturing technician
  • Lindsey Brede, financial controller
  • Dawnel Scott, director QA/RA
  • Mairi Maclean, director of product development
  • Nicole Bartnikowski, scientific manager (Australia)

“Having the ability to attract and hire individuals with the industry knowledge and pedigrees of this world-class team is a testament to how BiVACOR is perceived in the industry," Timms continues. "Each of them brings a unique perspective and skillset to BiVACOR and will play an important role in furthering our technology.”

BiVACOR is developing its Total Artificial Heart, or TAH. The device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

Coworking company opens new Houston location

Common Desk has a new West Houston location. Photo via Common Desk

Dallas-based Common Desk has announced the opening of its newest location in Westchase District. The flexible workspace company opened its first location in Houston in October 2020 and unveiled four more locations since then. The company shares in a news release that two more spots will be opening in 2022.

Common Desk - Westchase (2500 CityWest Blvd) ha 20,000 square feet of coworking space with 54 private offices, four office suites, six conference rooms, and shared space. Tenants will have access to an outdoor space, reserved and unreserved garage parking, a fitness center, and Common Desk's coffee brand, Fiction Coffee.

"When thinking about expanding our reach in the city, we knew we wanted to be somewhere in West Houston,” says Bobby Spoden, community sales manager at Common Desk, in the release. “Community comes first at Common Desk, and we love that the Westchase District shares the same value. We couldn't be more excited and honored to become part of the rich community in the West Houston area, and we're looking forward to the new additions to our vibrant member base."

Houston fintech unicorn expands on partnership with software company

HighRadius has deepened its partnership with Genpact. Photo via highradius.com

New York-based Genpact and Houston-based HighRadius announced the expansion of their strategic partnership. The expanded partnerships means the merging HighRadius's Autonomous Software platform with Genpact’s global accounts receivables and digital process and delivery expertise to enhance client experience across the board.

“Now more than ever, the finance function plays a vital role in leading businesses through crises, providing agility and insight that lead to greater resilience. To thrive, organizations must connect, predict and adapt at speed, placing data at their core and embracing digital technologies,” says Tiger Tyagarajan, CEO at Genpact, in a news release. “Bringing our two companies together in even deeper partnership will allow a new level of predictive intelligence that can derive meaningful insights and lead to impactful action for our clients.”

The duo originally teamed up in February of 2020 to bring together their expertise — digital automation solutions and advanced machine learning and artificial intelligence.

“If we paint the picture of the future of finance, and therefore the future of the CFO and the CFO organization, we think about the world of the CFO as one where technologies will basically allow them to make decisions every minute,” says Sashi Narahari, founder and CEO at HighRadius, in the release. “Prediction is what the machine will do. Decision, judgment and experience are never going to go away from human beings. So, humans are going to spend more time than they do today on decisions and examining business outcomes. That’s where the HighRadius and Genpact partnership can make a big difference.”

3 deadlines approach for Houston startup opportunities

Don't miss these three founder opportunities. Photo via Rice

Three different entrepreneurial opportunities have deadlines quick approaching.

  • The Rice Business Plan Competition, which is planned for April 7-9 this year, has its applications open until January 31. Any graduate-student startup, in a broad range of industries, from any university, in any degree program, in any country, can apply to the RBPC. Learn more about the competition and how to apply online at https://rbpc.rice.edu/compete.
  • Applications are open for the Black Girl Ventures Change Agent Fellowship, a nine-month leadership skills development program for Black and Brown women entrepreneurs and ecosystem builders. Selected applicants, who must be based in Los Angeles, New York, Chicago, Miami, Houston or Detroit, will each receive a $10,000 stipend. The time commitment is about 8 hours/month. The deadline to apply is January 31, 2022, and decisions will be made by mid-February. Learn more and apply at https://www.blackgirlventures.org/fellowship.
  • The 2022 HCC Business Plan Competition has applications open through January 28. The BPC will begin in late February and run through early June, with six free, virtual, 1.5 hour training  sessions. To learn more about the program and eligibility, click here.

Through a series B round and a federal grant, BiVACOR has raised $22 million in funding ahead of human trials. Photo via bivacor.com

Houston-based artificial heart company snags $22M in fresh funds

money moves

Houston-based medtech company BiVACOR has picked up $22 million in funding — in the form of a series B round and a federal grant — to propel development of its Total Artificial Heart device for treatment of severe heart failure.

In a May 19 news release, BiVACOR says it received a series B round of $19 million and a National Institutes of Health grant of $3 million. Boston-based Cormorant Asset Management and Australia's OneVentures, through its OneVentures Healthcare Fund III, led the round.

OneVentures first invested in BiVACOR three years ago. According to Australia's Financial Review, OneVentures initially pumped $3 million (Australian dollars) into BiVACOR, with the potential of contributing as much as $10 million if BiVACOR met certain milestones. BiVACOR received a round of seed funding from U.S. investors in 2013.

"BiVACOR's one-of-a-kind technology is supported by a remarkable team that has moved this technology a significant distance toward the clinic," Paul Kelly, managing partner of OneVentures, says in BiVACOR's news release.

The fresh cash will support preparation for the first human trials of the device. As a short-term measure, the device can be implanted in someone awaiting a heart transplant. It's also designed to be a long-term alternative to a heart transplant.

The BiVACOR device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

"The commitment and interest from our investors validate our technology and the need for improved options to treat end-stage biventricular heart failure," says Daniel Timms, founder and CEO of BiVACOR. "With this financing, we will be able to expand our world-class team and undertake … verification activities so that we can commence our first-in-human early feasibility study in the near future."

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

The company employs about a dozen people and says the funding will enable it to bring on another 10 employees.

For 13 years, BiVACOR has been working on technology aimed at eliminating the need for heart transplants. Thus far, the BiVACOR device has been tested only on cows.

"In heart failure, the heart becomes unable to pump enough blood to keep the body healthy and strong. At least 26 million people around the world are living with the disease, and the number is rising as populations age," IEEE Spectrum reported in 2019. "Patients with severe heart failure have a bleak outlook: Their best option is a heart transplant, but the limited number of donor hearts means that only about 5,000 patients around the world receive transplants each year. Thousands more patients are eligible for transplants, and some die while waiting for a donor organ."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Amazon's robotaxi service Zoox rolls out in 'sprawling' Houston market

On the Road

Amazon-owned robotaxi ride-hailing service Zoox is zooming into Houston in September, becoming the latest robotaxi operator jockeying for local riders.

Initially, self-driving retrofitted SUVs with safety drivers on board will serve downtown Houston, centrally located tourist hotspots, and certain residential neighborhoods. The SUVs will test Houston roads before Zoox rolls out autonomous robotaxis here, the company says.

Zoox takes Houston for a test drive

At the outset, Zoox says, a limited number of vehicles will be driven by people to gather data about Houston roads.

Zoox test drive Photo courtesy of Zoox

“This helps create a detailed picture of each street, from road geometry to traffic lights,” the company says. “Once we have mapped out an area, we will test autonomous driving capabilities. Safety and operational readiness govern the pace of our rollout.”

Zoox says its robotaxi differs from vehicles operated by other ride-hailing services.

The all-electric robotaxi “is purpose-built for autonomous ride-hailing and designed for riders from day one,” the company says. “It has no traditional driving controls and instead has carriage-style seating, sliding glass doors, and features that let the rider personalize their journey.”

To help manage the fleet, Zoox plans to open a depot in Houston for vehicle charging and maintenance, a representative says via email.

Along with Houston, Zoox is launching this month in San Diego. The ride-hailing service already operates in Austin, Dallas, Atlanta, Las Vegas, Los Angeles, Miami, Phoenix, the San Francisco Bay Area, Seattle, and Washington, D.C.

Zoox breaks into “sprawling” Houston market

Zoox describes Houston as its “most sprawling market to date.”

“Driving here means navigating complex service-road networks, unique merging scenarios, and challenging environmental conditions, including severe heat, heavy rain, and urban flooding,” the company says. “It’s a rigorous test of our technology across geography and terrain.”

Zoox will join two other autonomous ride-hailing services in Houston:

  • Waymo began rolling in Houston in February. Alphabet, the parent company of Google, owns Waymo.
  • Electric vehicle manufacturer Tesla began offering robotaxi services earlier this year.

A third Zoox competitor is arriving within the next year. A partnership comprising rideshare provider Uber, EV manufacturer Lucid, and autonomous technology company Nuro plans to launch a robotaxi service in Houston by mid-2027.

---

This article originally appeared on CultureMap.com.

Houston energy giant Shell lists local headquarters for sale for $325M

On the Market

Energy giant Shell has put its U.S. headquarters in Houston’s Energy Corridor on the market and is exploring the sale of its U.S. chemical business.

Green Street News reported Shell just listed its longtime Energy Corridor campus at 150 N. Dairy Ashford Road. The asking price is $325 million, The Real Deal reported. Shell plans to lease back half of the nearly 1.5 million-square-foot Woodcreek campus for 15 years.

A sale-leaseback deal could transform the 43.6-acre campus into a multitenant hub, CoStar News reported.

“Houston is a critical hub for Shell globally and the headquarters of our U.S. businesses,” a Shell spokesperson told the Houston Business Journal. “We remain committed to Houston and are evaluating opportunities to optimize our Woodcreek campus as part of our ongoing review of workplace needs while maintaining a strong presence in the city.”

Shell occupied its first building at the West Houston campus in 1980. The company employs more than 6,000 people in Texas.

Shell is one of the highest-profile businesses occupying space in the Energy Corridor. It’s home to 67,000 workers, more than 27 million square feet of office and mixed-use space, and 3.8 million square feet of retail and restaurant space.

Shell considers $8B sale of chemical business
As the company seeks to unload its Woodcreek campus, The Financial Times reported Shell is looking into selling its U.S. chemical business. The price tag: $8 billion.

Potential buyers include Spring-based ExxonMobil and Houston-based LyondellBasell.

Shell operates four chemical plants in Texas, Louisiana and Pennsylvania, producing an array of chemicals for use in plastics, detergents and pharmaceuticals.

Shell CEO Wael Sawan said last year that the company had spent $45 billion in capital “that is underperforming for us,” split between its chemical business and renewable energy arm.

Shell also agreed to sell its solar and wind power business in India this summer. Read more here.

---

This article originally appeared on EnergyCapitalHTX.com.

10+ can't-miss Houston business and innovation events for September

where to be

The energy transition and AI will be the talk of this town this month, thanks to a packed calendar of Houston events. September brings the return of Houston Energy and Climate Startup Week and some of its signature anchor events, plus AI conferences and talks exploring how the technology is impacting everything from healthcare to leadership. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


Sept. 3 — Entrepreneurship Roundtable with Open

Open Houston and the Ion present this roundtable event to bring together founders, builders, and innovators at various stages of venture development. This month's session will feature Faisal Bhutto, president and CEO of Houston-based AI and tech consulting firm Alykas.

This event is Thursday, Sept. 3, from 10-11:30 a.m. at the Ion. An optional lunch ticket is available for purchase. Register here.

Sept. 3 — AI Operator Spotlight: Houston’s Top AI Leaders Open Their Playbooks

The Houston AI Club, Allenix, the Ion District and Collide are bringing together industry leaders to share their expertise and first-hand experiences building AI companies. The event will feature a panel with Chuck Yates, co-founder of Collide, and Charles Jessup, senior manager of AI fluency at Raytheon, plus an open networking session.

This event is Thursday, Sept. 3, from 5:30-8 p.m. at the Ion. Register here.

Sept. 8 — The Technology Leadership Advantage Series – For CEOs, VCs and PE Firms

Ram Prasad, CEO of Houston-based IT consulting firm Delence, will explore the role of leadership in turning AI investments into business value during the latest installment of this series at the Ion. The event will explore why AI strategies often fail before the technology does and how companies should approach AI ownership, governance, investment and accountability.

This event is Tuesday, Sept. 8, from noon-1 p.m. at the Ion. Register here.

Sept. 14–18 — Houston Energy and Climate Startup Week

Houston Energy and Climate Startup Week returns for its third year, with panels, happy hours and pitch days focused on the energy transition. See the schedule of events here. The week will begin with a kickoff block party and open house at the Ion.

This event starts Monday, Sept. 14. The Ion District will host many of the week's events. Find more information here.

Sept. 15 — Meet the Activate Houston Cohort 2026 Fellows

Meet Activate's latest cohort, which was named this summer, and learn more about their hardtech and climate-focused solutions. Also meet founders from the organization’s 2025 cohort during Houston Energy and Climate Startup Week.

This event is Tuesday, Sept. 15, from 5-7 p.m. at the Ion. Register here.

Sept. 15 – Cypher Pilotathon and Startup Showcase

Grab coffee and take in keynotes and panels featuring leaders from Amperon, Aramco Ventures, New Climate Ventures, Syzygy Plasmonics and many others during this signature event, this year under the theme “The NEW Energy Industrial Revolution.” After lunch, hear pitches from 31 ventures during the Pilotathon. This year's event will also feature a startup showcase with interactive booths where attendees can meet founders and see demonstrations, plus an industry hub where corporates and investors can engage with emerging technologies and identify the pilots they want to move forward with.

This event is Tuesday, Sept. 15, from 9 a.m.-5 p.m. at POST Houston. Get tickets here.

Sept. 15-17 — The AI in Health Conference

Rice University's Ken Kennedy Institute will present this future-focused event, aimed at bridging the gap between artificial intelligence and real-world health outcomes. The event will feature panels with leaders from institutions and companies from around the world, plus technical talks, poster presentations and networking receptions.

This event begins Tuesday, Sept. 15 at 8 a.m. at the BRC at Rice University. Register here.

Sept. 16 — Greentown Labs Climatech Summit

Entrepreneurs, investors, corporate leaders, policymakers and philanthropists will head to Houston this month for the annual Greentown Climatetech Summit. Hear from Greentown CEO Georgina Campbell Flatter and keynote speaker Tim Latimer, CEO and co-founder of Houston geothermal unicorn Fervo Energy, plus numerous other engaging panels at the Ion. Then head to Greentown Labs for an open house and startup showcase, where attendees can meet some of the climatech incubators' members, before taking in the startup pitch competition followed by happy hour over at the Continental Club.

This event is Wednesday, Sept. 16, from 8 a.m.–9 p.m. at multiple locations. Register here.

Sept. 18 — Rice Alliance Energy Tech Venture Forum

Hear from clean energy startups from around the world at the 23rd annual Energy Tech Venture Forum. In addition to the pitches, this event will also host keynotes from Sean Maher, chief economist at Phillips 66, and Ira Ehrenpreis, founder and managing partner of DBL Partner. Panels will focus on technologies, infrastructure and commercialization strategies needed to deploy breakthrough innovations at scale. Following the event, the Rice Alliance will also name its annual “Most Promising” startup.

This event is Thursday, Sept. 17, from 7:30 a.m.-5 p.m. at Rice University’s Jones Graduate School of Business. Register here.

Sept. 23 – Houston Methodist Innovation Discussion

Houston Methodist presents its latest Innovation Discussion this month for the Houston health IT community. This month's event will feature Dr. Jordan Dale, chief medical information officer and chief health AI officer at Houston Methodist, and Ginny Torno, executive director of innovation and IT clinical, ancillary and research systems for Houston Methodist. The two will share insights into Houston Methodist’s innovation strategy and approach to scaling new ideas, plus real-world lessons on AI adoption and more.

This event is Wednesday, Sept. 23, from 5:30-7 p.m. at the Ion. Register here.

Sept. 23 — UH Energy Career Fair

Find your next job or team member at UH's energy-focused career fair. The event will feature companies from the fossil fuels, electrical power, nuclear power and renewables industries; plus nonprofits, governmental agencies and startups. And though the event is geared toward business, engineering, technology and science majors, it is open to students of all majors.

This event is Wednesday, Sept. 23, from 11 a.m.-2 p.m. at the UH Student Center. Find more information here.

Sept. 30 — First Principles Tech Talk: From Orbit to the Lunar Surface

Head to the Ion for the first-ever First Principles Tech Talk. This event will feature short talks and moderated discussions geared toward founders, engineers and operators in the commercial space industry. The inaugural event will feature Megan Ortiz and Zach Paugh from Houston-based Axiom Space.

This event is Wednesday, Sept. 30, from 5-7 p.m. at the Ion. Register here.

View All Listings